Fractyl Health shares rise 2.05% after-hours following HydroGraph's collaboration with Hawkeye Bio for lung cancer screening.

Fractyl Health, Inc. rose 2.05% in after-hours trading, following the announcement of a new lung cancer screening product by HydroGraph Inc. The product, LEAP, is a non-invasive, radiation-free, and highly sensitive blood test designed to detect early signs of lung cancer, even in asymptomatic patients. This collaboration between HydroGraph, Hawkeye Bio, and Ease Healthcare could potentially drive demand for Fractyl Health's technology, aligning with the stock's upward movement.